Point72 Asia Singapore Pte. Ltd. Buys New Stake in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)

Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) in the 2nd quarter, Holdings Channel reports. The firm acquired 18,027 shares of the company’s stock, valued at approximately $27,000.

Several other institutional investors have also bought and sold shares of the business. Marquette Asset Management LLC bought a new position in Reneo Pharmaceuticals during the first quarter valued at $122,000. Highbridge Capital Management LLC lifted its position in Reneo Pharmaceuticals by 6.5% during the second quarter. Highbridge Capital Management LLC now owns 2,915,376 shares of the company’s stock valued at $4,402,000 after purchasing an additional 178,806 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new stake in shares of Reneo Pharmaceuticals in the 2nd quarter worth about $846,000. Institutional investors own 90.98% of the company’s stock.

Insider Transactions at Reneo Pharmaceuticals

In other news, major shareholder Braden Michael Leonard bought 29,600 shares of the stock in a transaction dated Tuesday, September 24th. The stock was purchased at an average price of $1.41 per share, for a total transaction of $41,736.00. Following the acquisition, the insider now owns 3,388,649 shares of the company’s stock, valued at $4,777,995.09. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders bought 256,239 shares of company stock worth $355,105. 17.90% of the stock is currently owned by insiders.

Reneo Pharmaceuticals Trading Up 5.2 %

Reneo Pharmaceuticals stock opened at $1.82 on Tuesday. The firm has a 50-day moving average price of $1.49 and a 200-day moving average price of $1.59. The firm has a market capitalization of $60.83 million, a PE ratio of -0.84 and a beta of 0.21. Reneo Pharmaceuticals, Inc. has a 12-month low of $0.98 and a 12-month high of $9.21.

Reneo Pharmaceuticals (NASDAQ:RPHM) last released its earnings results on Tuesday, August 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. As a group, sell-side analysts predict that Reneo Pharmaceuticals, Inc. will post -0.65 earnings per share for the current fiscal year.

Reneo Pharmaceuticals Company Profile

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.